Immunotherapy plus chemo shows promise for esophageal cancer in early trial
NCT ID NCT06869213
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy before and after surgery can help patients with locally advanced esophageal cancer. About 30 participants will receive three cycles of the combination before surgery, then continue adebrelimab alone after surgery to prevent recurrence. The main goals are to see how many patients have no cancer cells left after treatment and to monitor side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Adebrelimab (a PD-L1 inhibitor) combined with nab-paclitaxel and cisplatin chemotherapy
- What this could lead to
- If successful, this could lead to a new treatment option that improves outcomes for patients with resectable esophageal cancer by using immunotherapy alongside standard chemotherapy before and after surgery.
- What could go wrong
- This is a small, early-phase (phase 2) study with only 30 participants, so results may not apply to everyone. The combination may cause significant side effects, and it is not yet proven to be better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER (ESC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Cancer Hospital
RECRUITINGBeijing, 100142, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads